Paclitaxel-loaded polymeric micelle (230 mg/m2) and cisplatin (60 mg/m2) vs. paclitaxel (175 mg/m2) and cisplatin (60 mg/m2) in advanced non-small-cell lung cancer

A multicenter randomized phase IIB trial

Sung Yong Lee, Hee Sun Park, Kye Young Lee, Hee Joung Kim, Young June Jeon, Tae Won Jang, Kwan Ho Lee, Young Chul Kim, Kyu Sik Kim, In Jae Oh, Sun Young Kim

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Paclitaxel-loaded polymeric micelle is a novel Cremophor EL-free formulation of paclitaxel that showed antitumor activity against nonsmall-cell lung cancer. We performed a phase IIB trial to evaluate that the response rate of paclitaxel-loaded polymeric micelle plus cisplatin is not inferior to those of a paclitaxel plus cisplatin regimen in patients with advanced nonsmall-cell lung cancer and who are chemonaive. The efficacy of paclitaxel-loaded polymeric micelle plus cisplatin was noninferior to that of paclitaxel plus cisplatin, and the overall incidence of adverse events was similar for both groups. Introduction The development of paclitaxel-loaded polymeric micelle (PPM) has circumvented many of the infusion-related difficulties associated with standard solvent-based paclitaxel. PPM plus cisplatin combination chemotherapy showed significant antitumor activity in phase I and II studies. This prospective randomized controlled phase IIB study assessed the noninferiority of the efficacy and tolerability of high-dose PPM plus cisplatin to a standard dose of paclitaxel plus cisplatin. Patients and Methods: Patients with stage IIIB/IV or recurrent non-small-cell lung cancer (NSCLC) who were chemonaive were eligible for participation. The patients were randomly assigned to receive PPM 230 mg/m2 plus cisplatin 60 mg/m2 or paclitaxel 175 mg/m 2 plus cisplatin 60 mg/m2 once every 3-week cycle. The primary endpoint was to compare the response rate (RR) between the groups with coprimary analyses to assess noninferiority. Secondary endpoints included progression-free survival, overall survival, and safety. Results: A total of 276 patients were randomized to PPM plus cisplatin (n = 140) or paclitaxel plus cisplatin (n = 136). RR was 43.6% in the PPM plus cisplatin group and 41.9% in the paclitaxel plus cisplatin group. Noninferiority of PPM plus cisplatin compared with paclitaxel plus cisplatin was confirmed for RR. There were no differences in progression-free survival and overall survival between the groups. Although there was a higher rate of grade 3 neutropenia in the PPM plus cisplatin group, the overall rate of adverse events was comparable between the 2 groups. Conclusion: PPM in combination with cisplatin was well tolerated, and its response rate was noninferior to that of paclitaxel plus cisplatin in patients with advanced NSCLC and who were chemonaive.

Original languageEnglish
Pages (from-to)275-282
Number of pages8
JournalClinical Lung Cancer
Volume14
Issue number3
DOIs
Publication statusPublished - 2013 Jul 15

Fingerprint

Micelles
Paclitaxel
Non-Small Cell Lung Carcinoma
Cisplatin
Disease-Free Survival
Survival
TP protocol
Combination Drug Therapy
Neutropenia

Keywords

  • Chemotherapy
  • Cisplatin
  • Non-small-cell lung cancer
  • Paclitaxel
  • Paclitaxel-loaded polymeric micelle

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

Paclitaxel-loaded polymeric micelle (230 mg/m2) and cisplatin (60 mg/m2) vs. paclitaxel (175 mg/m2) and cisplatin (60 mg/m2) in advanced non-small-cell lung cancer : A multicenter randomized phase IIB trial. / Lee, Sung Yong; Park, Hee Sun; Lee, Kye Young; Kim, Hee Joung; Jeon, Young June; Jang, Tae Won; Lee, Kwan Ho; Kim, Young Chul; Kim, Kyu Sik; Oh, In Jae; Kim, Sun Young.

In: Clinical Lung Cancer, Vol. 14, No. 3, 15.07.2013, p. 275-282.

Research output: Contribution to journalArticle

Lee, Sung Yong ; Park, Hee Sun ; Lee, Kye Young ; Kim, Hee Joung ; Jeon, Young June ; Jang, Tae Won ; Lee, Kwan Ho ; Kim, Young Chul ; Kim, Kyu Sik ; Oh, In Jae ; Kim, Sun Young. / Paclitaxel-loaded polymeric micelle (230 mg/m2) and cisplatin (60 mg/m2) vs. paclitaxel (175 mg/m2) and cisplatin (60 mg/m2) in advanced non-small-cell lung cancer : A multicenter randomized phase IIB trial. In: Clinical Lung Cancer. 2013 ; Vol. 14, No. 3. pp. 275-282.
@article{c0bf39f41c8a4063a10c756fab04c4fd,
title = "Paclitaxel-loaded polymeric micelle (230 mg/m2) and cisplatin (60 mg/m2) vs. paclitaxel (175 mg/m2) and cisplatin (60 mg/m2) in advanced non-small-cell lung cancer: A multicenter randomized phase IIB trial",
abstract = "Paclitaxel-loaded polymeric micelle is a novel Cremophor EL-free formulation of paclitaxel that showed antitumor activity against nonsmall-cell lung cancer. We performed a phase IIB trial to evaluate that the response rate of paclitaxel-loaded polymeric micelle plus cisplatin is not inferior to those of a paclitaxel plus cisplatin regimen in patients with advanced nonsmall-cell lung cancer and who are chemonaive. The efficacy of paclitaxel-loaded polymeric micelle plus cisplatin was noninferior to that of paclitaxel plus cisplatin, and the overall incidence of adverse events was similar for both groups. Introduction The development of paclitaxel-loaded polymeric micelle (PPM) has circumvented many of the infusion-related difficulties associated with standard solvent-based paclitaxel. PPM plus cisplatin combination chemotherapy showed significant antitumor activity in phase I and II studies. This prospective randomized controlled phase IIB study assessed the noninferiority of the efficacy and tolerability of high-dose PPM plus cisplatin to a standard dose of paclitaxel plus cisplatin. Patients and Methods: Patients with stage IIIB/IV or recurrent non-small-cell lung cancer (NSCLC) who were chemonaive were eligible for participation. The patients were randomly assigned to receive PPM 230 mg/m2 plus cisplatin 60 mg/m2 or paclitaxel 175 mg/m 2 plus cisplatin 60 mg/m2 once every 3-week cycle. The primary endpoint was to compare the response rate (RR) between the groups with coprimary analyses to assess noninferiority. Secondary endpoints included progression-free survival, overall survival, and safety. Results: A total of 276 patients were randomized to PPM plus cisplatin (n = 140) or paclitaxel plus cisplatin (n = 136). RR was 43.6{\%} in the PPM plus cisplatin group and 41.9{\%} in the paclitaxel plus cisplatin group. Noninferiority of PPM plus cisplatin compared with paclitaxel plus cisplatin was confirmed for RR. There were no differences in progression-free survival and overall survival between the groups. Although there was a higher rate of grade 3 neutropenia in the PPM plus cisplatin group, the overall rate of adverse events was comparable between the 2 groups. Conclusion: PPM in combination with cisplatin was well tolerated, and its response rate was noninferior to that of paclitaxel plus cisplatin in patients with advanced NSCLC and who were chemonaive.",
keywords = "Chemotherapy, Cisplatin, Non-small-cell lung cancer, Paclitaxel, Paclitaxel-loaded polymeric micelle",
author = "Lee, {Sung Yong} and Park, {Hee Sun} and Lee, {Kye Young} and Kim, {Hee Joung} and Jeon, {Young June} and Jang, {Tae Won} and Lee, {Kwan Ho} and Kim, {Young Chul} and Kim, {Kyu Sik} and Oh, {In Jae} and Kim, {Sun Young}",
year = "2013",
month = "7",
day = "15",
doi = "10.1016/j.cllc.2012.11.005",
language = "English",
volume = "14",
pages = "275--282",
journal = "Clinical Lung Cancer",
issn = "1525-7304",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - Paclitaxel-loaded polymeric micelle (230 mg/m2) and cisplatin (60 mg/m2) vs. paclitaxel (175 mg/m2) and cisplatin (60 mg/m2) in advanced non-small-cell lung cancer

T2 - A multicenter randomized phase IIB trial

AU - Lee, Sung Yong

AU - Park, Hee Sun

AU - Lee, Kye Young

AU - Kim, Hee Joung

AU - Jeon, Young June

AU - Jang, Tae Won

AU - Lee, Kwan Ho

AU - Kim, Young Chul

AU - Kim, Kyu Sik

AU - Oh, In Jae

AU - Kim, Sun Young

PY - 2013/7/15

Y1 - 2013/7/15

N2 - Paclitaxel-loaded polymeric micelle is a novel Cremophor EL-free formulation of paclitaxel that showed antitumor activity against nonsmall-cell lung cancer. We performed a phase IIB trial to evaluate that the response rate of paclitaxel-loaded polymeric micelle plus cisplatin is not inferior to those of a paclitaxel plus cisplatin regimen in patients with advanced nonsmall-cell lung cancer and who are chemonaive. The efficacy of paclitaxel-loaded polymeric micelle plus cisplatin was noninferior to that of paclitaxel plus cisplatin, and the overall incidence of adverse events was similar for both groups. Introduction The development of paclitaxel-loaded polymeric micelle (PPM) has circumvented many of the infusion-related difficulties associated with standard solvent-based paclitaxel. PPM plus cisplatin combination chemotherapy showed significant antitumor activity in phase I and II studies. This prospective randomized controlled phase IIB study assessed the noninferiority of the efficacy and tolerability of high-dose PPM plus cisplatin to a standard dose of paclitaxel plus cisplatin. Patients and Methods: Patients with stage IIIB/IV or recurrent non-small-cell lung cancer (NSCLC) who were chemonaive were eligible for participation. The patients were randomly assigned to receive PPM 230 mg/m2 plus cisplatin 60 mg/m2 or paclitaxel 175 mg/m 2 plus cisplatin 60 mg/m2 once every 3-week cycle. The primary endpoint was to compare the response rate (RR) between the groups with coprimary analyses to assess noninferiority. Secondary endpoints included progression-free survival, overall survival, and safety. Results: A total of 276 patients were randomized to PPM plus cisplatin (n = 140) or paclitaxel plus cisplatin (n = 136). RR was 43.6% in the PPM plus cisplatin group and 41.9% in the paclitaxel plus cisplatin group. Noninferiority of PPM plus cisplatin compared with paclitaxel plus cisplatin was confirmed for RR. There were no differences in progression-free survival and overall survival between the groups. Although there was a higher rate of grade 3 neutropenia in the PPM plus cisplatin group, the overall rate of adverse events was comparable between the 2 groups. Conclusion: PPM in combination with cisplatin was well tolerated, and its response rate was noninferior to that of paclitaxel plus cisplatin in patients with advanced NSCLC and who were chemonaive.

AB - Paclitaxel-loaded polymeric micelle is a novel Cremophor EL-free formulation of paclitaxel that showed antitumor activity against nonsmall-cell lung cancer. We performed a phase IIB trial to evaluate that the response rate of paclitaxel-loaded polymeric micelle plus cisplatin is not inferior to those of a paclitaxel plus cisplatin regimen in patients with advanced nonsmall-cell lung cancer and who are chemonaive. The efficacy of paclitaxel-loaded polymeric micelle plus cisplatin was noninferior to that of paclitaxel plus cisplatin, and the overall incidence of adverse events was similar for both groups. Introduction The development of paclitaxel-loaded polymeric micelle (PPM) has circumvented many of the infusion-related difficulties associated with standard solvent-based paclitaxel. PPM plus cisplatin combination chemotherapy showed significant antitumor activity in phase I and II studies. This prospective randomized controlled phase IIB study assessed the noninferiority of the efficacy and tolerability of high-dose PPM plus cisplatin to a standard dose of paclitaxel plus cisplatin. Patients and Methods: Patients with stage IIIB/IV or recurrent non-small-cell lung cancer (NSCLC) who were chemonaive were eligible for participation. The patients were randomly assigned to receive PPM 230 mg/m2 plus cisplatin 60 mg/m2 or paclitaxel 175 mg/m 2 plus cisplatin 60 mg/m2 once every 3-week cycle. The primary endpoint was to compare the response rate (RR) between the groups with coprimary analyses to assess noninferiority. Secondary endpoints included progression-free survival, overall survival, and safety. Results: A total of 276 patients were randomized to PPM plus cisplatin (n = 140) or paclitaxel plus cisplatin (n = 136). RR was 43.6% in the PPM plus cisplatin group and 41.9% in the paclitaxel plus cisplatin group. Noninferiority of PPM plus cisplatin compared with paclitaxel plus cisplatin was confirmed for RR. There were no differences in progression-free survival and overall survival between the groups. Although there was a higher rate of grade 3 neutropenia in the PPM plus cisplatin group, the overall rate of adverse events was comparable between the 2 groups. Conclusion: PPM in combination with cisplatin was well tolerated, and its response rate was noninferior to that of paclitaxel plus cisplatin in patients with advanced NSCLC and who were chemonaive.

KW - Chemotherapy

KW - Cisplatin

KW - Non-small-cell lung cancer

KW - Paclitaxel

KW - Paclitaxel-loaded polymeric micelle

UR - http://www.scopus.com/inward/record.url?scp=84879979431&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879979431&partnerID=8YFLogxK

U2 - 10.1016/j.cllc.2012.11.005

DO - 10.1016/j.cllc.2012.11.005

M3 - Article

VL - 14

SP - 275

EP - 282

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

SN - 1525-7304

IS - 3

ER -